Uveitis : Controlled clinical studies of patients with uveitis demonstrated that LOTEMAX (loteprednol etabonate ophthalmic suspension) was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with LOTEMAX (loteprednol etabonate ophthalmic suspension) experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP ( ≥ 10 mmHg) was 1% with LOTEMAX (loteprednol etabonate ophthalmic suspension) and 6% with prednisolone acetate 1%.
Lotemax is used in dry eye syndrome to decrease and eliminate inflammation of the ocular surface caused by the hyperosmolarity of the tears. The inflammation must first be brought under control before any other treatments can be optimally effective. Lotemax would typically be prescribed for two weeks to three months initially and then may need to be used again on a 1-2 week regimen periodically if the inflammation occurs again. Lotemax ointment has become a choice of many doctors to treat inflammation caused by dry eye (ocular surface disease) because it can be used at night with a long contact period to the eye's surfaces and provide some functional lubrication while the eyes are closed.